Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study.

Genomics - 1 Mar 2021

Chen Mu-Hong, Kao Chung-Feng, Tsai Shih-Jen, Li Cheng-Ta, Lin Wei-Chen, Hong Chen-Jee, Bai Ya-Mei, Tu Pei-Chi, Su Tung-Ping

Abstract excerpt

BACKGROUNDS: Evidence suggested the crucial roles of brain-derived neurotrophic factor (BDNF) and glutamate system functioning in the antidepressant mechanisms of low-dose ketamine infusion in treatment-resistant depression (TRD). METHODS: 65 patients with TRD were genotyped for 684,616 single nucleotide polymorphisms (SNPs). Twelve ketamine-related genes were selected for the gene-based genome-wide association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Brain-Derived Neurotrophic Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infusions, Intravenous

Share to Membrane Glycoproteins

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Share to Receptor, trkB

Share to Receptors, N-Methyl-D-Aspartate

Source

Identifiers

PMID: 33370585
DOI: 10.1016/j.ygeno.2020.12.030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study.PMID 33370585Read ↗

Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.Semantic proximity Read ↗

Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant DepressionSemantic proximity Read ↗

Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature ReviewSemantic proximity Read ↗

A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.Semantic proximity Read ↗

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets.Semantic proximity Read ↗

Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)Semantic proximity Read ↗

The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice.Semantic proximity Read ↗

Ketamine in severe, highly treatment-resistant depression—a retrospective case study and a perspectiveSemantic proximity Read ↗

GRIN2B Gene Polymorphism in Chronic Ketamine Users.Semantic proximity Read ↗

Treatment-resistant depression: molecular mechanisms and managementSemantic proximity Read ↗

Real-world patient characteristics, treatment patterns, efficacy and safety of intramuscular ketamine treatment: a retrospective cohort studySemantic proximity Read ↗

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extensionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.